704 related articles for article (PubMed ID: 1376346)
1. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
[TBL] [Abstract][Full Text] [Related]
2. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
3. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D
Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967
[TBL] [Abstract][Full Text] [Related]
4. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice.
Cruz LJ; Quintana D; Iglesias E; Garcia Y; Huerta V; Garay HE; Duarte C; Reyes O
J Pept Sci; 2000 May; 6(5):217-24. PubMed ID: 10823490
[TBL] [Abstract][Full Text] [Related]
6. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
7. A combinatorial peptide library around variation of the human immunodeficiency virus (HIV-1) V3 domain leads to distinct T helper cell responses.
Estaquier J; Boutillon C; Georges B; Ameisen JC; Tartar A; Auriault C
J Pept Sci; 1996; 2(3):165-75. PubMed ID: 9231325
[TBL] [Abstract][Full Text] [Related]
8. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
9. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
10. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
11. Site-directed primary in vitro immunization: production of HIV-1 neutralizing human monoclonal antibodies from lymphocytes obtained from seronegative donors.
Chin LT; Hinkula J; Levi M; Ohlin M; Wahren B; Borrebaeck CA
Immunology; 1994 Mar; 81(3):428-34. PubMed ID: 7515847
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of a self-assembling peptide derived from the envelope proteins of HIV type 1. An approach to heterovalent immunogens.
Tripathy SP; Kumar A; Manivel V; Panda SK; Rao KV
J Immunol; 1992 Jun; 148(12):4012-20. PubMed ID: 1534827
[TBL] [Abstract][Full Text] [Related]
13. Induction of V3-specific cytotoxic T lymphocyte responses by HIV gag particles carrying multiple immunodominant V3 epitopes of gp120.
Luo L; Li Y; Chang JS; Cho SY; Kim TY; Choi MJ; Cheong HS; Kim HJ; Ahn HJ; Min MK; Chun BH; Jung SM; Woo SG; Park SY; Kang CY
Virology; 1998 Jan; 240(2):316-25. PubMed ID: 9454705
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
15. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
[TBL] [Abstract][Full Text] [Related]
16. Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits.
Isaguliants MG; Kadoshnikov YP; Kalinina TI; Smirnov VD; Wahren B
Biochemistry (Mosc); 1998 May; 63(5):551-8. PubMed ID: 9632891
[TBL] [Abstract][Full Text] [Related]
17. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120.
Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK
Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543
[TBL] [Abstract][Full Text] [Related]
18. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
[TBL] [Abstract][Full Text] [Related]
19. The effect of a single amino acid substitution within the V3 loop of HIV-1 gp120 on HLA-DR1-restricted CD4 T-cell recognition.
Fernandez MH; Faith A; Higgins JA; Weber J; Rees AD
Immunology; 1995 Jun; 85(2):176-83. PubMed ID: 7642208
[TBL] [Abstract][Full Text] [Related]
20. Shared antigenic epitopes on the V3 loop of HIV-1 gp120 and proteins on activated human T cells.
Trujillo JR; Rogers RA; Brain JD
Virology; 1998 Jun; 246(1):53-62. PubMed ID: 9656993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]